Biogenomics Profile
Key Indicators
- Authorised Capital ₹ 390.02 Cr
as on 02-12-2024
- Paid Up Capital ₹ 383.51 Cr
as on 02-12-2024
- Company Age 22 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.98 Cr
as on 02-12-2024
- Satisfied Charges ₹ 4.72 Cr
as on 02-12-2024
- Revenue 25.48%
(FY 2024)
- Profit 25.23%
(FY 2024)
- Ebitda -2.57%
(FY 2024)
- Net Worth -18.20%
(FY 2024)
- Total Assets -13.82%
(FY 2024)
About Biogenomics
The Corporate was formerly known as Biogenomics Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 390.02 Cr and a paid-up capital of Rs 383.51 Cr.
The company currently has active open charges totaling ₹3.98 Cr. The company has closed loans amounting to ₹4.72 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Biogenomics Limited India are Abhishek Deshpande as CFO and Shilpa Shetty as Company Secretary. Archana Krishnan, Ranjan Mogre, Rajesh Dalal, and Seven other members serve as directors at the Company.
- CIN/LLPIN
U24234PY2002PLC009158
- Company No.
048821
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2002
- Date of AGM
24 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pondicherry
Industry
Company Details
- Location
Pondicherry, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Biogenomics Limited offer?
Biogenomics Limited offers a wide range of products and services, including Manufacturing & Assembling Services, Custom Manufacturing Service, Research and Development (R&D) Work, Product Development Research, Pharma & Bioanalytical Services, Pharmaceutical Services, Syringes, Insulin Syringe.
Who are the key members and board of directors at Biogenomics?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhishek Deshpande  | CFO | 20-Apr-2014 | Current |
| Shilpa Shetty | Company Secretary | 08-Apr-2024 | Current |
Board Members(10)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajesh Dalal | Director | 08-Dec-2023 | Current |
| Archana Krishnan | Whole-Time Director | 03-Feb-2006 | Current |
| Ranjan Mogre | Director | 31-Mar-2015 | Current |
| Vijayanand Bhate | Director | 31-Mar-2015 | Current |
| Pushkar Jauhari | Nominee Director | 19-Jun-2022 | Current |
| Namit Rustagi | Director | 28-Mar-2022 | Current |
Financial Performance and Corporate Structure Insights of Biogenomics.
Biogenomics Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 25.48% increase. The company also saw a substantial improvement in profitability, with a 25.23% increase in profit. The company's net worth observed a substantial decline by a decrease of 18.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biogenomics?
In 2024, Biogenomics had a promoter holding of 100.00% and a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Avtos Life Sciences Private LimitedActive 13 years 25 daysRanjan Mogre and Vijayanand Bhate are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 21 Mar 2024 | ₹3.98 Cr | Open |
Icici Bank Limited Creation Date: 11 Jan 2014 | ₹3.60 Cr | Satisfied |
U.C.O. Bank Creation Date: 10 Oct 2003 | ₹1.12 Cr | Satisfied |
How Many Employees Work at Biogenomics?
Biogenomics has a workforce of 193 employees as of Dec 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biogenomics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biogenomics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
